MiR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets

Blood

Volumn 116, Issue 3, 2010, Pages 437-445

  Girardot, Michael ^a,b   Pecquet, Christian ^a,b   Boukour, Siham ^c   Knoops, Laurent ^d   Ferrant, Augustin ^d   Vainchenker, William ^c   Giraudier, Stéphane ^c   Constantinescu, Stefan N ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; MICRORNA; MICRORNA 28; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR E2F6; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MESSENGER RNA; PRIMER DNA;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN TARGETING; THROMBOCYTE; UNTRANSLATED REGION; 3' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; BLOOD; CELL LINE; DOWN REGULATION; DRUG ANTAGONISM; GENETICS; MEGAKARYOBLAST; METABOLISM; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

3' UNTRANSLATED REGIONS; AMINO ACID SUBSTITUTION; BASE SEQUENCE; BLOOD PLATELETS; CELL LINE; DNA PRIMERS; DOWN-REGULATION; HUMANS; JANUS KINASE 2; MEGAKARYOCYTE PROGENITOR CELLS; MICRORNAS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, THROMBOPOIETIN; RNA, MESSENGER; STAT5 TRANSCRIPTION FACTOR;

EID: 77955895735     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-165985     Document Type: Article

References (45)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-375.
2. Adamson JW. Analysis of haemopoiesis: the use of cell markers and in vitro culture techniques in studies of clonal haemopathies in man. Clin Haematol. 1984;13(2):489-502.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
7. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. (Pubitemid 46193073)
8. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
9. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
10. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864-1871. (Pubitemid 43289364)
11. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338(9):572-580. (Pubitemid 28114645)
12. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006;108(12):3913-3915. (Pubitemid 44864576)
13. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
14. Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science. 1982;216(4551):1233-1235. (Pubitemid 12080055)
15. Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol. 1997;17(2):695-706. (Pubitemid 27044369)
16. Hendrie PC, Miyazawa K, Yang YC, Langefeld CD, Broxmeyer HE. Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. Exp Hematol. 1991;19(10):1031-1037.
17. Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985;41(3):727-734. (Pubitemid 15225429)
18. Komatsu N, Nakauchi H, Miwa A, et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 1991;51(1):341-348.
19. Dusa A, Staerk J, Elliott J, et al. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem. 2008;283(19):12941-12948.
20. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.
21. Aparicio O, Geisberg JV, Sekinger E, et al. Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol. 2005; Chapter 21:Unit 21.23.
22. Norol F, Vitrat N, Cramer E, et al. Effects of cytokines on platelet production from blood and marrow CD34+ cells. Blood. 1998;91(3):830-843. (Pubitemid 28078285)
23. Oberst A, Malatesta M, Aqeilan RI, et al. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci U S A. 2007;104(27):11280-11285. (Pubitemid 47175132)
24. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3(1):11-20.
25. Guy CT, Zhou W, Kaufman S, Robinson MO. E2F-1 blocks terminal differentiation and causes proliferation in transgenic megakaryocytes. Mol Cell Biol. 1996;16(2):685-693. (Pubitemid 26029628)
26. Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol. 1997;17(9):4991-5000. (Pubitemid 27357598)
27. Fiedler W, Henke RP, Ergun S, et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report. Cancer. 2000;88(2):344-351. (Pubitemid 30051818)
28. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. 2006;20(3):471-476. (Pubitemid 43291746)
29. Onishi M, Nosaka T, Misawa K, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998;18(7):3871-3879. (Pubitemid 28287910)
30. Petit MM, Mols R, Schoenmakers EF, Mandahl N, Van de Ven WJ. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics. 1996;36(1):118-129. (Pubitemid 26277765)
31. Rogalla P, Lemke I, Kazmierczak B, Bullerdiek J. An identical HMGIC-LPP fusion transcript is consistently expressed in pulmonary chondroid hamartomas with t(3;12)(q27-28;q14-15). Genes Chromosomes Cancer. 2000;29(4):363-366.
32. Dahéron L, Veinstein A, Brizard F, et al. Human LPP gene is fused to MLL in a secondary acute leukemia with a t(3;11) (q28;q23). Genes Chromosomes Cancer. 2001;31(4):382-389. (Pubitemid 32622715)
33. Kaushansky K. Etiology of the myeloproliferative disorders: the role of thrombopoietin. Semin Hematol. 2003;40(1 suppl 1):6-9. (Pubitemid 36403117)
34. Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age. Best Pract Res Clin Haematol. 2007;20(1):5-12. (Pubitemid 46300054)
35. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-1953. (Pubitemid 41713984)
36. Kikuchi J, Shimizu R, Wada T, et al. E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. Stem Cells. 2007;25(10):2439-2447.
37. Matsumura I, Nakajima K, Wakao H, et al. Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line. Mol Cell Biol. 1998;18(7):4282-4290. (Pubitemid 28287951)
38. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood. 1999;94(4):1273-1282.
39. Lambert JR, Gale RE, Linch DC. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia. Br J Haematol. 2009;145(1):128-130.
40. Saur SJ, Sangkhae V, Geddis AE, Kaushansky K, Hitchcock IS. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood. 2010;115(6):1254-1263.
41. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280(29):27251-27261.
42. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16(9):961-966.
43. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica. 2008;93(7):1009-1016.
44. Guglielmelli P, Tozzi L, Pancrazzi A, et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol. 2007;35(11):1708-1718.
45. Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell. 2008;14(6):843-853. (Pubitemid 351757199)